OVERVIEW OF ACTIVITY
Lung cancer is one of the most rapidly evolving fields in oncology nursing and is a major public health concern. In
2015, lung cancer will culminate in 221,200 new cases and an estimated 158,040 deaths in the United States.
Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of
patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a
modest effect on long-term outcomes. However, the advent of novel therapies has led to recent improvements in
disease-free and overall survival in select patient populations. Additionally, published results from ongoing clinical
trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To
provide oncology nurses with the current and necessary information to address the disparate needs of patients with
lung cancer, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists
and nurses who are experts in this disease. Upon completion of this CNE activity, oncology nurses should be able
to formulate up-to-date and more complete approaches to the care of patients with lung cancer.
PURPOSE STATEMENT
To present the most current research developments and to provide the perspectives of nurse practitioners and clinical investigators on the diagnosis and treatment of lung cancer.
LEARNING OBJECTIVES
- Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of lung cancer, including chemotherapy regimens and targeted biologic treatments.
- Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
- Recall the scientific rationale for the ongoing investigation of novel agents or immunotherapeutic approaches
in lung cancer, and counsel appropriately selected patients about study participation. - Establish an evidence-based approach to the selection of induction and maintenance biologic therapy and/or
chemotherapy for patients with advanced non-small cell lung cancer (NSCLC). - Assess emerging research on the benefits of early palliative care for patients with metastatic NSCLC, and
integrate this information, where appropriate, into patient consultations.
ACCREDITATION STATEMENT
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
ONCC/ILNA CERTIFICATION
CME credit is no longer available for this issue
FOR SUCCESSFUL COMPLETION
This is an audio program. The participant should listen to the audio MP3s.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Ms Goodwin had no real or apparent conflicts of interest to disclose. The following faculty (and
their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a
conflict of interest resolution process: Dr Wakelee — Consulting Agreement: Peregrine Pharmaceuticals Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation,
Clovis Oncology, Exelixis Inc, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc,
Roche Laboratories Inc, Xcovery. Dr Socinski — Advisory Committee: Bristol-Myers Squibb Company, Lilly,
Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals,
Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly, Pfizer
Inc, Takeda Oncology; Speakers Bureau: Celgene Corporation, Genentech BioOncology. Ms Eaby-Sandy — Advisory Committee: Clovis Oncology; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc,
Eisai Inc; Speakers Bureau: Amgen Inc, Celgene Corporation, Merck. Dr Langer — Advisory Committee: Abbott
Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation,
Clarient Inc, Clovis Oncology, Genentech BioOncology, Lilly, Merck, Myriad Genetic Laboratories Inc, Roche
Laboratories Inc; Consulting Agreements: Abbott Laboratories, Bayer HealthCare Pharmaceuticals, Boehringer
Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology,
Lilly, Merck, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company,
Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, Merck, Pfizer Inc, Takeda
Oncology, Veridex LLC; Data Safety Monitoring Committee: Amgen Inc, Synta Pharmaceuticals Corp.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas
Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare
Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc,
Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation,
Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc,
Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic
Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary,
Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau
Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology,
Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc, Celgene
Corporation, Genentech BioOncology, Lilly and Novartis Pharmaceuticals Corporation.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: May 2015
Expiration date: May 2016